Sensorion SA | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 89.3M
Total Liabilities 17.1M
Shareholders Equity 72.1M
Debt to Equity 0.24

Cash Flow Metrics

Revenue & Profitability Trend

Sensorion SA Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i004.0M3.3M1.9M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i25.7M22.8M22.9M14.6M7.7M
Selling, General & Administrative i4.5M2.4M130.6K106.0K99.4K
Other Operating Expenses i-3.7M-4.4M1.8M2.1M1.5M
Total Operating Expenses i26.4M20.8M24.9M16.8M9.3M
Operating Income i-28.4M-22.3M-23.1M-15.0M-8.9M
Operating Margin % i0.0%0.0%-574.1%-449.8%-463.0%
Non-Operating Items
Interest Income i2.9M708.0K95.6K53.6K43.4K
Interest Expense i251.0K109.0K168.0K165.7K132.3K
Other Non-Operating Income-----
Pre-tax Income i-25.8M-21.8M-23.2M-15.1M-9.0M
Income Tax i126.0K297.0K000
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-26.0M-22.1M-23.2M-15.1M-9.0M
Net Margin % i0.0%0.0%-576.8%-453.8%-468.7%
Key Metrics
EBITDA i-25.4M-21.5M-22.3M-14.5M-8.5M
EPS (Basic) i-€0.09-€0.18-€0.29-€0.19-€0.15
EPS (Diluted) i-€0.09-€0.18-€0.29-€0.19-€0.15
Basic Shares Outstanding i283969129122501538798370847969135860760952
Diluted Shares Outstanding i283969129122501538798370847969135860760952

Income Statement Trend

Sensorion SA Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i66.8M37.0M26.2M50.0M62.2M
Short-term Investments i10.2M----
Accounts Receivable i-----
Inventory i-----
Other Current Assets-8.7K14.1K545.5K34.7K
Total Current Assets i85.7M43.3M35.8M56.9M66.4M
Non-Current Assets
Property, Plant & Equipment i3.2M2.3M1.7M1.0M653.7K
Goodwill i746.0K506.0K483.1K569.7K589.6K
Intangible Assets i746.0K506.0K478.3K569.7K589.6K
Long-term Investments-----
Other Non-Current Assets3.0K-211.0K--11
Total Non-Current Assets i3.6M3.2M3.2M2.1M1.5M
Total Assets i89.3M46.5M38.9M59.1M67.9M
Liabilities
Current Liabilities
Accounts Payable i6.9M3.7M7.3M5.0M2.2M
Short-term Debt i1.2M1.1M1.2M711.4K303.1K
Current Portion of Long-term Debt-----
Other Current Liabilities91.0K237.0K477.5K400.0K170.0K
Total Current Liabilities i13.7M9.6M13.6M10.5M4.3M
Non-Current Liabilities
Long-term Debt i1.0M1.8M2.6M3.4M3.6M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities2.2M1.6M681.5K1.0M1.5M
Total Non-Current Liabilities i3.5M3.6M3.5M4.5M5.2M
Total Liabilities i17.1M13.2M17.1M15.0M9.5M
Equity
Common Stock i30.1M18.7M8.0M8.0M8.0M
Retained Earnings i-61.9M-58.6M-23.2M-15.1M-9.0M
Treasury Stock i82.0K86.0K---
Other Equity-----
Total Shareholders Equity i72.1M33.3M21.9M44.1M58.4M
Key Metrics
Total Debt i2.2M2.9M3.9M4.1M3.9M
Working Capital i72.0M33.7M22.2M46.4M62.2M

Balance Sheet Composition

Sensorion SA Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-26.0M-22.1M-23.2M-15.1M-9.0M
Depreciation & Amortization i-----
Stock-Based Compensation i1.0M298.0K1.1M561.1K359.0K
Working Capital Changes i184.0K-831.0K-2.5M482.9K2.2M
Operating Cash Flow i-24.7M-22.5M-24.6M-14.1M-6.3M
Investing Activities
Capital Expenditures i-705.0K-657.0K-1.4M-470.0K-75.8K
Acquisitions i-----
Investment Purchases i--6.1K-29.6K-33.3K0
Investment Sales i-----
Investing Cash Flow i-719.0K-669.1K-1.5M-503.3K-75.8K
Financing Activities
Share Repurchases i-----3.4K
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-893.0K-1.1M---20.0M
Financing Cash Flow i67.0M33.1M-488.0K-557.6K37.3M
Free Cash Flow i-22.5M-21.6M-22.9M-11.4M-5.5M
Net Change in Cash i41.5M10.0M-26.5M-15.2M31.0M

Cash Flow Trend

Sensorion SA Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -3.63
Forward P/E -2.52
Price to Book 1.36
Price to Sales 16.08
PEG Ratio -2.52

Profitability Ratios

Profit Margin 0.00%
Operating Margin -371.94%
Return on Equity -49.28%
Return on Assets -26.15%

Financial Health

Current Ratio 6.28
Debt to Equity 2.93
Beta 1.13

Per Share Data

EPS (TTM) -€0.09
Book Value per Share €0.24
Revenue per Share €0.02

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
alsen107.0M-3.631.36-49.28%0.00%2.93
Medincell S.A 557.6M-18.19-61.33%-66.50%-1.44
Abivax SA 547.1M-3.08-82.88-196.12%0.00%-16.16
Innate Pharma S.A 158.3M-2.8216.36-162.91%-245.87%350.86
Ose 120.5M3.611.8186.29%44.88%72.30
Transgene S.A 110.8M-6.96-220.48%0.00%68.38

Financial data is updated regularly. All figures are in the company's reporting currency.